Introduction
============

Small GTPases are defined by their basic biochemical activity of binding GTP and hydrolyzing it to GDP, which is called the guanosine triphosphate (GTP)/guanosine diphosphate (GDP) cycle ([@B25]). Although similar to the heterotrimeric G protein α subunits in biochemistry and function, small GTPases function as monomeric G proteins ([@B43]). In addition to their high affinity and hydrolysis activity for GTP, small GTPases have two states, a GTP-bound state and a GDP-bound state. The activated small G-proteins are mainly regulated by three crucial factors: Guanosine nucleotide dissociation inhibitors (GDIs), guanine nucleotide exchange factors (GEFs) and GTPase activator proteins (GAPs) ([@B27]; [@B263]; [@B142]). [Figure 1](#F1){ref-type="fig"} shows a simple schematic diagram of their function. In this cycle, GAPs promote GTP hydrolysis, and GEFs stimulate the exchange of GDP for GTP ([@B153]). GDIs can be defined as a class of proteins interacted with small GTPases, which not only prevent exchange (maintaining the small GTPases in an off-state), but also prevent the small GTPase from localizing at the membrane ([@B38]). Importantly, these molecular switches affect almost all cellular processes such as gene expression, microtubule organization, cytoskeleton reorganization, and vesicular and nuclear transport ([@B107]). Small GTPases can also be influenced by post-translational modifications such as phosphorylation or ubiquitination, which can regulate protein stability and subcellular localization ([@B1]).

![The two state of small GTPases. GTP- and GDP-bound state are regulated by GEFs and GAPs. GEFs stimulate the exchange of GDP for GTP, resulting activation of Ras ("ON"). GAPs promote GTP hydrolysis, and return Ras to GDP-bound state ("OFF").](fnmol-12-00121-g001){#F1}

To date, 167 small GTPases have been identified in humans ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}) ([@B195]; [@B142]). We compared the G-domin region of those small GTPases, and found that there exist 5 repeated sequences. After removing 5 repeated amino acid sequences that are identical, the resulting 162 amino acid sequences were analyzed and a sequence-homology based phylogenetic tree ([Figure 2](#F2){ref-type="fig"}) was constructed using the Neighbor-Joining method ([@B200]). According to sequence and functional similarity, small GTPases can be divided into five main families whose eponymous members are Ras, Rho, Rab, ADP-ribosylation factor (Arf) and Ran ([@B272]). Ras family members, the first members of the superfamily to be discovered, are signal nodes mediating the responses to various extracellular stimuli and can regulate cell proliferation, differentiation, morphology, and apoptosis by binding to a variety of effector molecules with different catalytic activities to regulate the cytoplasmic signaling network ([@B114]). The Rho family includes more than 20 proteins. This family is known for its role in actin cytoskeleton remodeling and cell polarity ([@B71]; [@B97]). The three best known members are Rho (A, B, C), Rac and Cdc42 ([@B246]; [@B220]; [@B190]; [@B43]). Among them, RhoA, Rac1, and Cdc42 have been studied the most ([@B211]; [@B196]; [@B85]). The Rab family is by far the largest family of the Ras superfamily in humans ([@B195]). Proteins of this family participate in vesicle formation, movement and fusion, and vesicular cargo trafficking ([@B174]; [@B213]). The Arf family includes 30 proteins and is also involved in vesicle trafficking. Ran is the only member found in the Ran family, which is present in all eukaryotic lineages and involved in nuclear transport ([@B271]).

![Evolutionary relationships of human Ras superfamily. The evolutionary history was inferred using the Neighbor-Joining method. After removing identical sequences, 162 amino acid sequences ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}) are used for the analysis. All ambiguous positions were removed for each sequence pair. The original classification was indicated by different colors: Ras (lilac), Rho (cyan), Rab (purple), Arf (red), Ran (green), and Unclassified members (blank). Evolutionary analyses were conducted in MEGA7.](fnmol-12-00121-g002){#F2}

All the proteins have a GTP-binding domain of about 20 kDa, also known as the G-domain ([@B25]; [@B246]). As shown in [Figure 3](#F3){ref-type="fig"}, this domain consists of five α helices (A1--A5), six β-strands (B1--B6) and five polypeptide loops (G1--G5). This domain is highly conserved overall, and especially the loops ([@B170]). When bound to GDP, small GTPases are inactive. The two states have similar conformations and can be distinguished by two functional loop regions: switch I (corresponds to the G2 loop) and switch II (corresponds to the G3 loop and part of the A2 helix) ([Figure 3](#F3){ref-type="fig"}) ([@B109]; [@B170]). The G1 loop is located between the B1 strands and A1 helix with the motif X~1~X~1~X~1~GXXXXGK (S/T), where X~1~ is leucine (L), valine (V) or isoleucine (I), and X is any amino acid. The α- and β-phosphate groups can be bound to this motif ([@B117]). The G2 loop, with only one conserved threonine (T), that connects the A1 helix and the B2 strand is responsible for the binding of Mg^2+^ via conserved amino acid residues. The G3 loop is at the N-terminus of the A2 helix with the motif XXXXDXXGX. Its main function is to bind Mg^2+^ and the γ-phosphoric acid group of GTP or GDP. The G4 loop containing the motif XXX (G/A) (T/N) KXD and the G5 loop are mainly responsible for the recognition of the guanine base ([Figure 4](#F4){ref-type="fig"}). Although the G-domain is conserved in the superfamily, there are also individual difference among the different small GTPase families. For example, in G1 loop, the sixth position G is only conserved in the Rho, Rab, and Arf families. On the other hand, covalent post-translational modification by lipids is another feature of small GTPases. These modifications are essential for facilitating membrane association and subcellular localization, which is critical for their respective biological activities ([@B91]; [@B182]). The C-terminal cysteine residue of the motif can be prenylated by farnesyltransferase or geranylgeranyltransferase. This modification was observed for most Ras, Rho, and Rab family members despite the different motifs, which is composed of CAAX (C is Cys, A is aliphatic and X is any amino acid) for Ras and Rho family proteins, and CC, CXC, CCX, CCXX, or CCXXX for the Rab family ([@B46]; [@B272]). Some Ras superfamily members without lipid modification, such as Rit, RhoBTB, Miro, and Sar1, can also associate with membranes ([@B272]). Arf family proteins lack C-terminal lipid modification signals and some members are modified at their N-termini by a myristoylation ([@B44]). By contrast, Ran does not exhibit any detectable modification by lipids and binding to membranes ([@B272]).

![Structures analysis of Ras. The crystal structures of Ras GDP Mg^2+^ complex (PDB 4q21) is showed (upper). This structure contains five α-helices (A1--A5), six β-strands (B1--B6), and five polypeptide loops (G1--G5) and the position relationship among various parts is displayed (below).](fnmol-12-00121-g003){#F3}

![Conservation analysis of the 167 human G-domain of Ras superfamily and its subfamilies (<http://meme-suite.org/>). Considering that the Ran only has one sequence and is a branch of Rab subfamily, we incorporate Ran into Rab family.](fnmol-12-00121-g004){#F4}

Studies of the functions of Ras superfamily proteins in modulating the diverse signaling cascades have established many current fundamental paradigms of signal transduction, mainly based on decades of oncological investigations. The awareness of aberrant Ras-related signaling in the pathogenesis of other human disorders has also risen in recent years. Here we highlight the critical roles of each family of the Ras superfamily in non-neoplastic cerebral diseases ([Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}), which in turn may suggest novel therapeutic targets for developmental diseases and cognitive impairments.

###### 

Gene mutations related to Small GTPases (Ras family).

  Gene mutations        Related disease            Proteins                                               Pathway/mechanism                                                      References
  --------------------- -------------------------- ------------------------------------------------------ ---------------------------------------------------------------------- ------------------
  *PTPN11*              NS                         SHIP2: Protein tyrosine phosphatase                    Increased RAS/MAPK                                                     [@B226]
  *PTPN11*              NS-ML                      SHIP2: Protein tyrosine phosphatase                    Increased AKT/mTOR                                                     [@B244]
  *SOS1*                NS                         Son of sevenless homolog 1                             Increased RAS/MAPK, Rac, and Stat3                                     [@B260]
  *RAF1*                NS                         v-Raf-1 murine leukemia viral oncogene homolog 1       Increased RAS/MAPK                                                     [@B280]
  *RAF1*                NS-ML                      v-Raf-1 murine leukemia viral oncogene homolog 1                                                                              
  *KRAS*                NS                         V-Ki-Ras2 Kirsten rat sarcoma viral oncogene homolog   Increased RAS/MAPK                                                     [@B249]
  *KRAS*                CFCS                                                                                                                                                     
  *NRAS*                NS                         Neuroblastoma Ras viral (V-Ras) oncogene homolog       Increased RAS/MAPK                                                     [@B65]
  *SHOC2*               NS                         soc-2 suppressor of clear homolog                      SHOC2-MRAS-PP1 complex positively regulates RAF activity               [@B282]
  *SHOC2*               NS-LAH                     soc-2 suppressor of clear homolog                                                                                             
  *BRAF*                NS                         Serine/Threonine-Protein Kinase B-Raf                  Increased RAS/MAPK                                                     [@B249]
  *BRAF*                CFCS                       Serine/Threonine-Protein Kinase B-Raf                  Increased RAS/MAPK, Decreased p38 and AKT                              [@B249]
  *RIT1*                NS                         Ras-Like Without CAAX 1                                Increased RAS/MAPK                                                     [@B5]
  *RRAS*                NS                         Related Ras viral (R-Ras) Oncogene Homolog             Related RAS Viral (R-Ras) Oncogene Homolog; Increased RAS/MAPK         [@B69]
  *MAP3K8*              NS                         RAS/MARK pathway                                       Increased RAS/MAPK                                                     [@B251]
  *MEK1*                CFCS                       MEK 1: Mitogen-activated protein kinase kinase 1       Increased RAS/MAPK                                                     [@B53]
  *NF1*                 NF-1                       Neurofibromin                                          PI3K/mTOR/AKT pathway                                                  [@B7]
  *SPRED1*              LS                         Sprouty-related EVH1 domain containing protein 1       Increased RAS/MAPK and JAK2                                            [@B98]
  *SPRED2*              OCD                        Sprouty-related EVH1 domain containing protein 2       Loss of SPRED2                                                         [@B256]
  *HRAS*                CS                         Harvey rat sarcoma viral oncogene homolog              Increased RAS/MAPK                                                     [@B16]
  *RIT2* (rs12456492)   Parkinson's disease        CD33                                                   rs12456492 polymorphism is associated with increased CD33 expression   [@B144]
  *RIT2* (rs12456492)   Essential tremor           --                                                     --                                                                     [@B66]
  *RIT2* (rs16976358)   Autism spectrum disorder   Regulatory motif of the SOX transcription factor       rs16976358 variant                                                     [@B89]
  *RIT2* (rs16976358)   Schizophrenia              --                                                     CNV                                                                    [@B187]; [@B248]
  *RIT2* (rs16976358)   Bipolar disorder           --                                                     --                                                                     [@B66]
  *RIT2* (rs4130047)    Autism spectrum disorder   --                                                     --                                                                     [@B89]
                                                                                                                                                                                 

NS, Noonan syndrome; NS-ML, Noonan syndrome with multiple lentigines; NS-LAH, Noonan-like syndrome disorder with loose anagen hair; CS, Costello syndrome; CFCS, Cranio-facio-cutaneous syndrome; LS, Legius syndrome; OCD, Obsessive compulsive disorder; NF-1, Type 1 neurofibromatosis; CNVs, Copy number variations

.

###### 

Interacting proteins related to Small GTPases (Ras family).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Small GTPase   Interacting proteins   Related diseases/function                                                                                   Pathway/mechanism                                                         References
  -------------- ---------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -----------------
  Rit2 (Rin)     NGF                    Alzheimer's disease                                                                                         Increased RAS/MAPK                                                        [@B17]

                                        Huntington's disease                                                                                        Increased AKT/mTOR                                                        [@B34]; [@B291]

                 RIT1                   Noonan syndrome                                                                                             Increased RAS/MAPK, Rac, and Stat3                                        [@B278]

                                        Mental retardation, microcephaly, and epilepsy                                                                                                                                        [@B231]

                 TECR                   Non-syndromic mental retardation                                                                            Increased RAS/MAPK                                                        [@B30]

                 NTRK1                  Hereditary sensory and autonomic neuropathy type V                                                          A mutation in the *NTRK1*/high-affinity nerve growth factor (TrkA) gene   [@B100]

                                        Congenital insensitivity to pain with anhidrosis                                                                                                                                      

                 POU4F1                 Autism                                                                                                      Copy number variations (CNVs)                                             [@B102]

  Rit1 (Rit)     B-Raf                  Neuronal development and regeneration                                                                       Activation of the B-Raf/ERK and p38 MAP kinase cascades                   [@B201]

                 p38 MAPK               Neurite outgrowth and cell survival                                                                                                                                                   

                 MK2                    Cell survival                                                                                               Rit GTPase-p38-MK2-AKT 9 kinase survival pathway                          [@B221]

                 HSP27                  Cell survival                                                                                               MK2 signaling complex                                                     [@B222]

                 Akt                    Cell survival                                                                                               p38--MK2--HSP27-Akt activation                                            [@B223]

                 RGL3                   RalA activation                                                                                             A candidate effector for Rit and Ras                                      [@B216]

  Rheb           mTOR                   Promoting growth, cell cycle progression and inhibition of autophagy                                        Growth factor-induced mTORC1 activation                                   [@B230]

                 TSC complex            Form a complex with Rheb at the lysosomal membranes                                                         Growth factor-induced mTORC1 activation                                   [@B139]

                 PLD1                   Rheb binds and activates phospholipase D1 (PLD1) in a GTP-dependent manner                                  mTORC1 activation                                                         [@B295]

                 GAPDH                  GAPDH regulates mTOR activity by sequestering the Rheb.                                                     Rheb--GAPDH interaction                                                   [@B129]

                 FKBP38                 Coordinate membrane targeting of Rheb                                                                       Rheb interacts with FKBP38 and prevents its association with mTOR         [@B51]

                 RASSF1                 Rheb form complex with RASSF1A to coordinate Hippo and TOR signaling                                        Hippo pathway activator                                                   [@B166]

                 NIX\                   Rheb interacts with mitochondrial autophagic receptor Nix and the autophagosomal protein LC3-II.            Activation of mitophagy                                                   [@B154]\
                 LC3                                                                                                                                                                                                          [@B240]

                                                                                                                                                                                                                              

                 Syntenin               PDZ protein syntenin preferentially binds to the GDP-bound form of Rheb.                                    Rheb-syntenin signaling                                                   [@B206]

                 CAD                    Rheb binds to CAD protein, a multifunctional enzyme required for the synthesis of pyrimidine nucleotides.   CAD binding is more pronounced with Rheb2 than with Rheb1                 [@B254]

                 PERK                   Rheb inhibits protein synthesis by activating the PERK-eIF2α signaling                                      Phosphorylation of eIF2α and PERK interplay                               [@B214]

                 BACE1                  Aging and Alzheimer's disease. Forebrain Rheb promotes aging-associated cognitive defects                   Rheb depletion increased the levels of BACE1                              

                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Small GTPases and Related Diseases (Rho, Arf, Rab, and Ran families).

  Small GTPase     Related disease                                                          Pathway/mechanism                                                                                                                    References
  ---------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------
  Rac3             A novel neurodevelopmental syndrome                                      De novo monoallelic missense variants in Rac3, including one recurrent change                                                        [@B45]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  RhoA             Diabetic Parkinson's disease or dementia                                 Accelerated neuron loss via the 5-hydroxytryptamine 2 receptor                                                                       [@B298]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Cdc42            Epileptic-seizures                                                       Regulating synaptic inhibition                                                                                                       [@B290]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rac1             Fragile X syndrome                                                       Rac1 is necessary for normal spine development and long-term synaptic plasticity                                                     [@B18]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rac1             Epilepsy                                                                 Patients suffering from temporal lobe epilepsy (TLE) and experimental epileptic rats                                                 [@B137]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  RhoB             Glioblastoma                                                             Cytokine-induced STAT3 activation, activated p53 and p21                                                                             [@B146]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rac1 and Cdc42   Developmental delay, secondary macrocephaly, seizures, and ataxic gait   De novo PAK1 mutations c.392A\>G (p.Tyr131Cys) and c.1286A\>G (p.Tyr429Cys)                                                          [@B94]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rac1             Drug withdrawal                                                          Rac1-dependent GABAAR endocytosis, synaptic plasticity as well as learning and memory                                                [@B268]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rac1             Alcohol use disorders                                                    Rac1/Arfaptin/Arf6 pathway                                                                                                           [@B175]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  RhoA             Cocaine                                                                  Phosphorylated ERM levels and synaptic changes in the NAcc                                                                           [@B116]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab7             Parkinson's disease                                                      Clearance of α-synuclein aggregates                                                                                                  [@B203]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab11            Parkinson's disease                                                      Reduces α-synuclein aggregation and toxicity                                                                                         [@B41]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab39b           Parkinson's disease                                                      Reduce steady-state levels of α-synuclein                                                                                            [@B274]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab              Infantile encephalopathy                                                 Rab GTPase-Activating Protein dysregulates mTOR signaling                                                                            [@B40]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab1A            Alzheimer's disease                                                      Mediates Golgi dynamics                                                                                                              [@B157]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab3A            Alzheimer's disease                                                      Localizes in presynaptic vesicles and regulates exocytosis                                                                           [@B255]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab4             Alzheimer's disease                                                      Regulates endosomal recycling                                                                                                        [@B77]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab5             Alzheimer's disease                                                      Modulates endosomal membrane trafficking, sorting and endosomal fusion                                                               [@B75],[@B76]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab6             Alzheimer's disease                                                      Regulates retrograde Golgi-ER trafficking                                                                                            [@B209]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab7A            Alzheimer's disease                                                      Controls transport to late endosomes and lysosomes/regulates tau secretion                                                           [@B77]; [@B192]; [@B285]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab8             Alzheimer's disease                                                      Modulates polarized trafficking                                                                                                      [@B224]; [@B111]; [@B136]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab10            Alzheimer's disease                                                      pRab10-T73, decrease in Aβ42 and Aβ42/Aβ40 ratio                                                                                     [@B191]; [@B277]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab11A/Rab11B    Alzheimer's disease                                                      Regulates both endocytic and exocytic trafficking pathways                                                                           [@B255]; [@B28]; [@B276]; [@B294]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab14            Alzheimer's disease                                                      Endocytic recycling and Golgi-endosome trafficking                                                                                   [@B141]; [@B181]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab17            Alzheimer's disease                                                      Involved in phagocytic removal of apoptotic cells                                                                                    [@B255]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab24            Alzheimer's disease                                                      Involved in autophagy                                                                                                                [@B75]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab27            Alzheimer's disease                                                      Regulates exocytosis, endocytosis and phagocytosis                                                                                   [@B77]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab36            Alzheimer's disease                                                      Involved in late endosome and lysosome distribution                                                                                  [@B255]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab3a            Glioma                                                                   Increases cyclin D1 expression                                                                                                       [@B115]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab38            Glioblastomas                                                            Whole genome mRNA expression microarray data on 220 glioma samples from the Chinese glioma genome atlas                              [@B266]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Rab28            Cone-rod dystrophy                                                       Retinal dystrophies                                                                                                                  [@B198]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arf1             Creutzfeldt-Jakob disease                                                Arf/Rho/MLC signaling                                                                                                                [@B284]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arl2 and Arl3    Retina disease                                                           Participate in the trafficking of lipidated membrane-associated proteins and colocalize in the inner segment with UNC119A and PDEδ   [@B261]; [@B289]; [@B92],[@B93]; [@B160]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arf6             Alcohol use disorders                                                    Rac1/Arfaptin/Arf6 pathway                                                                                                           [@B175]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arl6             Diabetic retinopathy                                                     Regulates VEGFR2 trafficking and signal transduction                                                                                 [@B296]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arl6             ALS                                                                      Potential driver pathophysiological events involving endoplasmic reticulum stress and autophagy                                      [@B288]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arf72A           Retina disease                                                           Rescues the ninaE(D1)-related membrane accumulation and suppresses ninaE(D1)-triggered retinal degeneration                          [@B127]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Arl2             Bardet--Biedl syndrome type 3                                            Disrupt a threonine residue important for GTP binding and function of several related small GTP-binding proteins                     [@B67]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Ran              Frontotemporal dementia                                                  Regulates nuclear import via TDP-43 pathway                                                                                          [@B269]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Ran              Alzheimer's disease                                                      Transcription regulators in the nucleus                                                                                              [@B152]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
  Ran              Glioblastoma multiforme                                                  The Survivin-Ran complex                                                                                                             [@B86]
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                 

ALS, amyotrophic lateral sclerosis.

The Ras Family in Non-Neoplastic Cerebral Diseases
==================================================

The Ras Family
--------------

As the first described and prototypical members of the small GTPase superfamily, Ras family proteins are almost universal components of signaling pathways in eukaryotic organisms, including vertebrates, invertebrates, and yeasts ([@B80]). Ras genes were first identified as oncogenes, and were named after the Rat Sarcoma gene in the 1970s during the extensive study of acutely transforming retroviruses isolated from mice, rats, and other animals ([@B47]). Following years of investigation, the widespread prevalence of Ras mutations in the context of carcinogenesis has now been widely recognized. This has inspired multiple attempts to find Ras inhibitors. However, as for the role of the Ras family in non-neoplastic diseases, we are still at the beginning stage of discovering how the related proteins and their precise mechanisms control and modulate non-oncogenic processes ([@B107]).

According to their evolutionarily conservation in structural, biochemical, and functional levels, the Ras family is composed of over 36 members, with six major subfamilies: Ras subfamily (H-Ras, K-Ras, N-Ras, etc.), Ral (RalA, RalB), Rap (Rap1, Rap2), Rad (Rad, Gem, etc.), Rheb (Rheb1, and Rheb2 or RhebL1) and Rit (Rit1 or Rit, Rit2 or Rin, and *Drosophila dRic*) ([@B80]).

Most Ras family proteins are predominantly localized on the intracellular surface of the plasma membrane as a result of C-terminal prenylation ([@B44]). They can be activated in response to multiple extracellular stimuli in the form of growth factors and small molecules, which thereby transduce signals to the intracellular environment to regulate cytoplasmic signaling networks ([@B279]).

The best-characterized downstream signaling cascade of Ras family proteins is the Mitogen-Activated Protein Kinase (MAPK) cascade, mainly the Extracellular signal-Regulated Kinase 1/2 (ERK) of the MAPK family ([@B279]). Ras family proteins can directly bind to the regulatory domain of Raf (c-Raf or b-Raf) and subsequently phosphorylate and dephosphorylate it at multiple sites for full activation. In turn, activated Raf phosphorylates and activates MAP Kinase or ERK Kinase (MEK), and finally targets transcription factors to induce gene expression ([@B124]). Take Rap subfamily members for example. Rap1 can activate ERK by activating b-Raf (expressed predominantly in the brain) and p38MAPK, which implies a pivotal role in synaptic depression ([@B83]; [@B112]). Furthermore, Rap2 is involved in the activation of c-Jun N-terminal Kinase (JNK) ([@B148]). In addition to the Raf--MEK--ERK cascade, other well-known pathways include the phosphatidylinositol 3-kinase (PI3K), RalGEF-Ral, and phospholipase C epsilon (PLCε) pathways ([@B184]; [@B202]).

The Rit subfamily is composed of two classes, Rit and Rin (Ras like without CAAX2, Rit2), each containing a well-conserved GTPase core (G1--G5). Distinct patterns of developmental expression for both proteins were found, whereby Rit is widely expressed throughout development, while Rin shows delayed expressed limited to later stages of embryonic neuronal development (E14), with highest Rin expression found in the adult brain ([@B222]; [@B89]). Activated Rit was identified as playing a critical role in the regulation of neuronal morphogenesis, especially enhancing axonal growth, but with the opposite effect on dendritic growth ([@B132]).

Rin is involved in calcium-mediated processes in cells and binds to calmodulin through a C-terminal binding motif, regulating the Rin-mediated pathway ([@B99]; [@B48]). Rin has an important role in intracellular signaling and interacts with DAT (dopamine active transporter) in lipid raft microdomains ([@B165]).

The Rheb subfamily (Ras homolog protein enriched in the brain) is a member of the Ras family that is highly conserved among different organisms ([@B258]; [@B210]). Two different Rheb genes have been identified in mammalians, *RHEB1* (from here on *REHB*), and *RHEB2* (also as *RHEBL1*). RHEB is expressed in various human tissues, but RHEB2 is mainly expressed in the brain tissue, such as cerebral cortex, occipital pole, frontal, and temporal lobes ([@B199]; [@B210]).

Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that integrates signals to regulate cell growth and metabolism. In the brain, Rheb functions as a key activator of mTORC1, and deletion of RHEB causes decreased cortical thickness and defective myelination ([@B128]).

RalA and RalB are monomeric GTPases belonging to the Ral subclass, and both are expressed in the nervous system ([@B250]). Ral can be activated either by Ras indirectly via a Ral-GEF (Guanine nucleotide Exchange Factor) or by Ca^2+^/calmodulin binding, and it is inactivated by PKC phosphorylation of the effector Sec5 ([@B95]; [@B37]). During brain development, it is considered that Ral is involved in the asymmetric division of neuroblasts, neuronal migration in the neocortex, neurite branching, and activity-dependent spine growth ([@B50]). RalA regulates axon initiation in cortical neurons by promoting an interaction between the exocyst protein complex, which is one of its major effectors, and the Par3--Par6--aPKC complex, an evolutionarily conserved master regulator of cell polarity. However, in other cell migration process, such as tumor metastasis, it seems that RalB may play a more important role than RalA ([@B286]).

The Rap subfamily is composed of five related proteins, Rap1 (A and B) and Rap2 (A, B, and C), which have overlapping functions and expression patterns ([@B162]; [@B292]). Similar to other members of the Ras family, Rap proteins work as molecular switches of multiple signal transduction cascades and are linked to several genetic defects related to mental, neurological and psychiatric disorders ([@B264]). Rap1 has been intensively investigated for its function in integrin-mediated cell adhesion and the regulation of cell--cell junction integrity ([@B108]). A recent study indicates that Rap1 and Rap2 predominantly signal synaptic depression via the lysosomal p38MAPK and the bulk membrane JNK pathway, respectively, regulating different forms of synaptic plasticity ([@B292]). Especially, Rap1B acts as a core molecule in the signaling network responsible for neuronal polarization ([@B162]).

Diseases Related to the Ras Family
----------------------------------

Owing to the Ras family proteins' essential role in modulating a wide range of cellular processes, several human diseases are caused by the dysregulation or dysfunction of related signaling pathways. These include cancer, developmental-, neurocognitive- and neurodegenerative disorders, as well as metabolic and cardiovascular diseases ([@B163]). In this section, we reviewed some Ras family related developmental disorders and neurological diseases.

### RASopathies

The RASopathies are the largest known group of rare human developmental disorders that are caused by germline mutations in genes that encode proteins of the RAS/MAPK pathway, resulting in its hyperactivation ([@B245]). As mentioned above, the RAS/MAPK pathway is essential for the development of mammalian tissues, controlling a variety of cellular activities, such as cell cycle and growth, differentiation, metabolism and senescence ([@B228]). Although this signaling pathway is often summarized as a well-established cascade, there are still many gray areas and multilevel regulations, such as transcriptional control, posttranslational modifications, protein-protein interactions, and crosstalk with other signaling pathways. In this section, we mainly focus on individual symptoms, phenotypes and most evidenced gene mutations to the RASopathies. Further detailed information on comprehensive functional and pathophysiological consequences could be referred to suggested reviews ([@B10]; [@B227]).

The RASopathies includes neurofibromatosis type 1 (NF1), Legius syndrome (LS), capillary malformation--arterio-venous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-facio-cutaneous syndrome (CFC), Noonan syndrome (NS) and Noonan syndrome with multiple lentigines (NS-ML) ([@B227]; [@B49]). Although RASopathies exhibit unique phenotypes, they share many overlapping clinical characteristics due to the common pathway dysregulation, such as partial facial anomalies, cognitive impairment, and congenital heart defects ([@B163]). As a whole, the RASopathies affect approximately 1 per 1,000 live births ([@B245]). The initial diagnosis of a RASopathy patient is based on the clinical recognition of phenotypic features, and the clinical diagnosis is then confirmed by molecular genetic tests. To date, with the accumulation of genotype and phenotype correlation data, there are more than 20 gene mutations has been associated with RASopathies. Most mutations causing RASopathies occur at conserved positions within the RAS/MAPK pathway, providing a genetic foundation for their diagnosis and pathophysiology ([@B227]). [Table 1](#T1){ref-type="table"} has listed several gene mutations related to small GTPases, especially the Ras family and RASopathies. However, considering the heterogeneity of a given syndrome and the pleiotropic roles during development and homeostasis maintenance, it is still difficult and fragmental to classify the causal genes and mutations involved with the genotype/phenotype correlations based on current progress.

NS was first described by Jacqueline Noonan about 50 years ago, and is also the most frequent RASopathy. Its estimated prevalence is between 1 in 2,000--2,500 newborns ([@B168]; [@B245]). It is an autosomal dominant disorder and the most genetically diverse RASopathy, which is clinically characterized by facial dysmorphic features, congenital heart defects, and growth retardation. More than half of patients with NS are identified as having mild to moderate developmental delay/learning disability, notably with social and communication difficulties, attention deficit, and language impairment ([@B33]). Most of the mutations responsible for NS affect familiar components of Ras pathways. The protein tyrosine phosphatase non-receptor type (*PTPN11*), encoding SHP2, is the first and major NS disease gene, which was found mutated in 50--60% of patients with NS ([@B10]). Other less common or rare mutation genes are related to the RAS/MAPK pathway as well, including SOS1, SOS2, H-Ras, K-Ras, R-Ras, N-Ras, M-Ras and Rit1, the GAP RasA2, the kinases CRAF, BRAF, MEK1, MEK2, and MAP3K8, CBL, MYST4, A2ML1, SHOC2, and its binding partner PP1 ([@B252]). SHOC2 mutations have been reported in combination with mutations in PTPN11 (SHP2) in NS ([@B64]). The diversity of the affected genes has determined the NS is the most genetically heterogeneous RASopathy. However, the role of these proteins in regulating the RAS/MAPK pathway is still not clear, and the underlying functional mechanisms and genotype/phenotype correlations remain to be elucidated ([@B252]; [@B227]).

NS-ML, formerly known as LEOPARD syndrome, is an autosomal dominant disorder that has a prevalence of fewer than 1 in 100,000 newborns ([@B204]). However, considering that the phenotype of NS-ML is very close to that of NS, the diagnosis can be more difficult ([@B204]). Distinctive clinical features for NS-ML are a high prevalence of hearing deficits (20%) and multiple pigmented skin lesions called lentigines, mostly starting at school age (90%) ([@B204]). Missense mutations in PTPN11 ([@B131]; [@B56]) and rarely in RAF1 ([@B172]) and BRAF ([@B56]) are associated with NSML. Loss of function mutations in the PTPN11 gene result in reduced SHP2 activity, which is not found in NS ([@B55]; [@B120]). A recent study implied that the Ras-related Akt-mTOR signaling pathway is implicated in NS-ML phenotypes ([@B151]).

Noonan-like syndrome with loose anagen hair (NSLAH), also known as Mazzanti syndrome, is phenotypically close to NS, but patients display distinctive hyperactive behavior and pathognomonic hair anomalies ([@B84]). SHOC2 and PPP1CB have been indicated with the onset of the disease ([@B10]). NF1, the second-most frequent RASopathy, is an autosomal dominant genetic disorder that was first described in 1882 ([@B74]; [@B227]). The incidence of NF1 is 1 per 2,500--3,000 in newborns, with approximately 50% of NF1 patients inheriting the mutation from a parent ([@B273]). The characteristic feature used for NF1 diagnosis is the presence of café-au-lait macules. Benign tumors (neurofibromas and optic pathway gliomas), iris Lisch nodules, bone malformations (limb pseudarthrosis), cardiac malformations, brain malformations, seizures, and mild neurocognitive impairment can aid the diagnosis ([@B101]; [@B236]). NF1 is caused by mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a GAP that negatively regulates Ras ([@B32]; [@B131]). NF1 mutations result in the loss of function of neurofibromin, which in turn reduces Ras GTPase activity and finally increases the levels of active GTP-bound Ras. Studies have suggested that neurofibromin can act on M-Ras, R-Ras, and R-Ras2 (a.k.a. TC21) ([@B169]). R-Ras and N-Ras activate PI3Kγ, while M-Ras recruits SHOC2/PP1c to the plasma membrane to regulate SCRIB activity ([@B193]; [@B283]). As a consequence, the loss of neurofibromin may have broader impacts on cells than the activation of H-Ras, N-Ras, and K-Ras proteins themselves ([@B227]).

Legius syndrome is a milder form of neurofibromatosis type 1, which shares phenotypic features with NF1, albeit in less severe form ([@B245]). However, the NF1 gene is intact and heterozygous inactivating mutations in the SPRED1 gene on chromosome 15q13.2 occur in LS ([@B26]). SPRED1 functions as a negative regulator of Ras by inhibiting the phosphorylation of Raf ([@B265]). The SPRED1 proteins are essential for the interaction of neurofibromin with Ras at the plasma membrane. It is suggested that SPRED2 and SPRED3 proteins can partially compensate the loss of SPRED1 function ([@B227]). Although SPRED1 binding does not affect neurofibromin's GAP activity, it nevertheless plays an important role in enabling neurofibromin to downregulate Ras activity at the plasma membrane.

CFCS is a rare autosomal dominant disease with multiple congenital anomalies that affects 1/800,000 newborns ([@B177]). It shares many overlapping features with NS (e.g., heart defects, short stature, and facial features) but is additionally characterized by thick scaly skin, delayed growth and cardiac malformations ([@B186]). Affected individuals frequently have severe neurological disturbances and mental retardation ([@B281]). CFCS is caused by heterozygous mutations in BRAF (75% of cases), and less frequently in the MAP2K1 (MEK1), MAP2K2 (MEK2) (20% of cases) and *k-ras* genes ([@B194]). BRAF is a downstream effector of Ras, and activating BRAF can increase the activation of the MAPK pathway by CRAF ([@B96]).

Costello syndrome is a multiple congenital anomaly syndrome caused by heterozygous activating germline mutations in HRAS. A common and distinctive feature of CS among RASopathies is an increased risk of developing cancers such as rhabdomyosarcomas and neuroblastomas. A recent study has found an increased energy expenditure (EE) in patients with CS, resulting in growth failure ([@B134]).

CM-AVM is associated with arteriovenous malformations and fistulas, and is caused by heterozygous inactivating mutations in RASA1 ([@B62]). RASA1 encodes p120-RasGAP, which is a negative regulator of the RAS/MAPK signal transduction pathway. RASA1 mutations have also been associated with the related condition known as Parkes Weber syndrome ([@B13]).

From the functional perspective, the global relationship for different syndromes could emerged as this: NS and NS-ML are mainly related with activators of the RAS/MAPK cascade (i.e., RAS or RAF activators), but NF and LS are associated to RAS inhibitors. In addition, CS and CFCS mutations hit the backbone of the pathway, while CS being centered on RAS and CFCS on downstream kinases ([@B10]).

#### Future prospective

With the continuous investigation and further understanding of causal mutations and functional analysis of pathophysiological consequences of RASopathies, tremendous advances have been made in the past 30 years. Whereas, given the current fragmentary view, the complexity of RASopathies determined that more issues and challenges lie ahead, such as unidentified causal genes in patients with RASopathies, further functional analyses of the newly discovered mutations, the precise mechanisms underlying the RASopathies (similarities and differences between RASopathies), and the variable expression of a gene mutation ([@B10]). In addition, we should take into account of the endocrine and metabolic prospective to interrogate the interactions and contributions of different mutations to the homeostasis imbalance and global phenotype. Moreover, additional factors, such as environmental, age-related and sex-related modifiers, may multifold the difficulty to decipher its pathophysiological process.

### Neurological and Psychiatric Disorders

Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder, affecting more than 30 million people worldwide ([@B237]). The disorder is characterized by early deficits in learning and memory followed by loss of other higher cognitive functions, which is correlated with synaptic depression and then neuronal degeneration ([@B87]). It is still unclear that what factors determined the age of onset and how the selective dysfunction of neurons in the brain been affected. A hallmark of AD pathology is the generation of amyloid beta (Aβ) from the amyloid precursor protein (APP) by APP-cleaving enzyme 1 (β-secretase, BACE1) ([@B210]). Studies showed the underlying mechanism for physiological regulating BACE1 stability and activity in its GTP-bound state was Rheb GTPase, which induced mammalian target of rapamycin (mTOR) activity. Protein levels of BACE1 and Aβ generation are suppressed upon Rheb overexpression ([@B210]). The interaction of GTP-activated Rheb with BACE1 stimulates its degradation via the proteasomal and lysosomal pathways ([@B215]). Recently correlation study implied that the nutrient signaling might regulate cognitive functions in mammals by regulating Rheb--BACE1 and Rheb--mTOR pathways activity, which also orchestrated a potential new therapeutic target for Alzheimer's-associated memory dysfunction ([@B214]).

Parkinson's disease (PD) is the second most common neurodegenerative disorder following Alzheimer's disease, affecting 1--2% of the population above 60 years of age ([@B113]). Although most PD cases occur sporadically, mutations in several genes, such as *SNCA* (α-synuclein), *PARK2* (parkin), *DJ-1*, *PINK1*, *ATP13A2*, *VPS35* (vacuolar protein sorting 35), *EIF4G1* (eukaryotic initiation factor 4G1) and *LRRK2* (leucine-rich repeat kinase 2), have been identified in hereditary PD ([@B253]). LRRK2 is a large, multifunctional protein with a central catalytic GTPase/kinase core flanked by several protein-binding domains. Seven missense mutations, clustered in the Ras-of-complex (ROC) GTPase domain, C-terminal-of-ROC (COR) and kinase domains, segregate with PD in affected families ([@B9]; [@B176]). Dopaminergic signaling also plays a critical role in the pathogenesis of PD, and dopamine transporter (DAT) serves as a primary mechanism for terminating dopaminergic signaling ([@B222]). Rit2 (Rin) was recently identified as a protein that interacts with the DAT C-terminal endocytic domain, implying a role of Rin signaling in the regulation of DAT trafficking ([@B165]). In addition, studies from the perspective of immunity have also indicated that Rit2 polymorphisms affect the innate immune system, which in turn is responsible for some PD symptoms ([@B35]). Recent genome wide association study (GWAS) and meta-analysis results introduced Rit2 as a novel susceptibility locus, in association with decreased Rin expression in the substantia nigra pars compacta (SNc) of PD patients ([@B21]; [@B125]; [@B173]). However, the results of RIT2 polymorphisms studies in different populations are controversial, which may be due to genetic context difference and environmental factors ([@B48]). Therefore, further functional study, animal study and larger study with various population samples might give more detailed role of RIT2 in cells and groups in PD pathogenesis.

Huntington's disease (HD) is a fatal autosomal-dominant neurodegenerative disease caused by CAG repeat expansion in exon 1 of *huntingtin*, which encodes the protein huntingtin (Htt). HD results in early loss of medium spiny neurons in the striatum, which impairs motor and cognitive functions ([@B147]). In HD, Htt contains an expanded poly-glutamine (poly-Q) tract. Under healthy conditions, Htt promotes signaling through mTORC1 (mammalian target of rapamycin complex 1). In the case of HD, the poly-Q tract potentiates the signaling by promoting the formation of a ternary complex of Htt-Rheb-mTOR, leading to enhanced mTORC1 activity ([@B205]). In the striatum, Rhes (Ras homolog enriched in the striatum) serves as a key activator of mTORC1 ([@B183]). Knockout of Rhes reduces mTORC1 activity and attenuates the adverse responses of L-DOPA-induced dyskinesia ([@B238]; [@B128]). In addition, Rhes facilitates SUMOylation, a process implicated in HD pathogenesis ([@B239]). Because Rhes is highly expressed in the striatum ([@B232]), it has been proposed that Rhes-Mutant Htt interactions may underlie the prominent striatal degeneration observed in HD. There is evidence that impaired Rhes/mTORC1 activity is relevant to the notable striatal pathogenesis in HD, which suggests that impaired mTORC1 function may represent a fundamental mechanism underlying the complex disease phenotypes of HD ([@B128]).

Autism spectrum disorders (ASD) are a continuum of complex neurological disorders interfering with normal social behavior and cognitive development ([@B89]). They are common neurodevelopmental diseases with onset prior to the age of three, affecting almost 1% of individuals worldwide ([@B143]). Children with ASD often show a large head circumference and develop epilepsy, and nearly half display severe intellectual disability ([@B237]). ASD has a strong but complex genetic component. A recent study identified an increase in RIT1 transcript levels in patients with autism, implying that Rit may represent an ASD susceptibility gene ([@B73]). Considering that several factors, such as abnormal assembly of synapses and dendritic spines, contribute to autism's pathogenesis, the Rit signal pathway that regulates synaptic development and function might be a novel potential therapeutic target ([@B61]).

Schizophrenia is a devastating psychiatric disorder characterized by reality distortion, with onset in late adolescence and unclear etiology ([@B79]). Common features are positive symptoms, such as hallucinations, delusions, disorganized speech, and negative symptoms, such as social deficits, lack of motivation, anhedonia, and impaired emotion processing, as well as cognitive deficits with occupational dysfunction ([@B6]). Previous studies have reported various copy number variations (CNVs) related to schizophrenia ([@B178]; [@B297]). Several recent studies have suggested that the *rit2* gene might be involved in the pathogenesis of schizophrenia ([@B79]). When compared with control subjects, patients with schizophrenia present a significant enrichment of common interstitial deletions ([@B22]). Among the deleted genes, *rit2* was identified as a candidate gene for language delay, mental retardation, and behavioral abnormalities ([@B22]). Evidence indicates that *ret* and *rit2*, both Ras-related genes important for neural crest development, are significantly affected by CNVs ([@B79]). Rit2 is involved in the ubiquitin E3 ligase growth factor pathway that affects mitochondrial dysfunction, which is linked with both schizophrenia and autism ([@B180]).

The protein interactions in the cells are common. Malfunction or alterations in the protein-protein interaction may influence vast biological functions. Selected members of Ras subfamily and their related possible interacting proteins are listed in the [Table 2](#T2){ref-type="table"}. Specifically for RIT2, evidence suggests that proteins interacting with RIT2 may cause or relate to similar clinical signs or diseases, which implied that RIT2 might be a potential candidate gene underlying several neurological diseases, such as PD, schizophrenia and autism ([@B48]).

Considering the new insight of the role of members of Ras subfamily in neuro- psychiatric disorders and metabolic regulation, substantial novel therapies might be developed or repurposed based on the extensive studies of Ras subfamily signaling in the context of cancer. For example, evidence suggests trametinib, a small molecule inhibitor targets the MEK kinase with high specificity, extends lifespan in *Drosophila* and protects against the malfunction of genetic induced obesity in mice ([@B229]).

The Rho Subfamily in Non-Neoplastic Cerebral Diseases
=====================================================

In the mid-1980s, [@B149] serendipitously identified the first Ras homolog in *Aplysia* sea slugs, and named it Rho. In recent decades, the Rho subfamily of small GTPases has been shown to regulate many aspects of basic cellular processes such as cell polarity, cell movement, cell--cell interaction, cell proliferation and differentiation, cell morphology, secretion, adhesion, gene expression and survival ([@B270]; [@B24]; [@B42]; [@B175]; [@B80]). More than 20 Rho members, which are structured into six subclasses, are found in all eukaryotic cells as a molecular switch for actin cytoskeleton reorganization ([@B88]; [@B164]). The Rho subfamily of small GTPases plays essential roles from changes in intracellular cytoskeleton dynamics to extracellular message exchange ([@B287]). In particular, Rho GTPases regulate dendritic arborization, spine morphogenesis, growth cone development, and axon guidance ([@B233]). The Rho subclass, including RhoA, RhoB, and RhoC, predominantly promotes the formation of actin stress fibers and focal adhesion ([@B8]; [@B68]). The Rac subclass (Rac1, Rac2, Rac3, and RhoG) promotes actin chain formation during the branching of lamellipodia, and the cell division cycle. 42 GTP-binding protein (Cdc42) subclass (Cdc42, TC10/RhoQ and TCL/RhoJ) mainly controls the formation of actin microspikes and filopodia ([@B12]; [@B80]).

Rho signaling is involved in several cerebral diseases, including intellectual disability (ID), epilepsy, drug addiction, HD, amyotrophic lateral sclerosis (ALS), and AD, and it acts by regulating axonogenesis, neuronal migration and synaptic plasticity ([Table 3](#T3){ref-type="table"}) ([@B155]; [@B145]; [@B290]; [@B137]; [@B268]; [@B298]; [@B45]). Rac1 and Rac3 are associated with intelligence by regulating key cellular functions in the central nervous system ([@B188]; [@B45]). Moreover, it was confirmed that missense mutations in Rac3 cause severe intellectual disability and brain malformations in humans ([@B45]). Previous studies have shown that X-linked ID is related to mutations in genes that code for regulators of the small-GTPase family such as Rac/Cdc42 guanine nucleotide exchange factor 6 (αPIX), RhoGEF and trio Rho guanine nucleotide exchange factor (TRIO) ([@B133]; [@B188]; [@B287]).

Rac1 is essential for diverse forms of learning, and contributes to extinction of an established memory during drug withdrawal or alcohol use disorders ([@B175]; [@B268]). A recent study provided evidence that Rac1-dependent GABA-A receptor endocytosis plays a crucial role in the extinction of aversive memories ([@B268]). Furthermore, Rho signaling is involved in regulating neuronal synaptic plasticity in the nucleus accumbens (NAc) and ventral tegmental area (VTA), which both play crucial roles in the reward circuitry ([@B52]). These actions of Rho-associated kinase (ROCK) signaling might also be related to synaptic plasticity in the lateral amygdala and prelimbic prefrontal cortex, which were also identified as regulators in reward circuits ([@B123]; [@B242]). Furthermore, these studies have shown that Rac1 plays a role in drug addiction by regulating synaptic plasticity and the neuronal projection network. It has also been observed that cocaine reduces the phosphorylation of Ezrin/Radixin/Moesin proteins (ERM) in the NAc by downregulating RhoA-Rho kinase signaling, which may importantly contribute to the initiation of synaptic changes in this site, leading to drug addiction ([@B116]).

Cdc42 is a small GTPase of the Rho-subfamily that acts as a multifaceted key regulator of neuronal structure and function ([@B29]; [@B82]; [@B290]). Cdc42 plays an important role in regulating epileptic seizures ([@B290]). Cdc42 regulates the availability of presynaptic sites for CaV2.1 calcium channel incorporation ([@B36]; [@B70]), and presynaptic activation of Cdc42 can mimic the effects of electrical activity that promotes synaptic maturation and plasticity ([@B218]). Cdc42 is over-expressed in the human cortex of the temporal lobe and in the hippocampus of intractable epilepsy patients after an anterior temporal lobectomy ([@B275]). [@B290] demonstrated the effect of Cdc42 on the function of hippocampal CA1 pyramidal neurons and revealed that blocking Cdc42 decreases the spontaneous action potentials (APs), and increases both the miniature inhibitory postsynaptic current (mIPSC) and evoked inhibitory postsynaptic current (eIPSC) ([@B290]).

Although Rho subfamily has gained the most attention for its putative role in numerous neurodegenerative diseases, the precise mechanisms as a therapeutic target remain controversial and uncertain. In PD, Rho signaling pathway is a promising therapeutic target ([@B121]). Some studies also suggest that mutations in LRRK2 can lead to a decrease in activation of Rac1 related Rho signaling, which causes disassembly of actin filaments leading to modulate cytoskeletal outgrowth and vesicular dynamics, including autophagy ([@B19]). These functions likely impact modulation of α-synuclein aggregation and associated toxicity in the pathophysiology of PD ([@B119]). A previous study revealed that ROCK inhibition protects against neuronal death induced by neurotoxins ([@B20]). ROCK regulation may provide a new neuroprotective strategy for neurodegenerative diseases, and it has to be settled urgently to develop more potent and selective ROCK regulators.

The Rab Subfamily in Non-Neoplastic Cerebral Diseases
=====================================================

The Rab subfamily, which comprises more than 60 members, is currently the largest branch of the Ras superfamily of small GTPases ([@B272]; [@B54]). This protein family is primarily related to various aspects of membrane and protein traffic in the endocytic and secretory pathways ([@B272]; [@B38]; [@B80]; [@B72]). Therefore, dysregulation of Rab GTPases may lead to the pathogenesis of some diseases ([Table 3](#T3){ref-type="table"}). Many neurodegenerative diseases are characterized by dysfunction of membrane and protein traffic in neurons ([@B293]). The Rab subfamily has also been related to neurodegenerative disorders such as Alzheimer's disease and PD ([@B274]; [@B203]; [@B277]). Previous studies have shown that Rab3A, Rab6, Rab8A/Rab8, Rab23, and Rab27b are highly expressed in the brain and participate in synaptic vesicle exocytosis, postsynaptic glutamate receptor dynamics, neurite growth and neural development ([@B247]; [@B167]; [@B257]). Rab3 is the most abundant Rab protein in the brain. It is localized in synaptic vesicles and participates in their fusion and neurotransmitter release ([@B167]; [@B225]).

Alzheimer's disease is clinically characterized by progressive cognitive impairment and memory loss ([@B14]). Two classical pathological features of AD are aberrant phosphorylated forms of tau protein and pathologically generated Aβ peptides ([@B130]; [@B2]; [@B14]; [@B23]; [@B241]). Rab GTPases are implicated in multiple pathological mechanisms, including Aβ production and accumulation in AD ([@B135]; [@B191]; [@B192]; [@B277]). Rab1B was found to play a key role in APP trafficking from the ER to the Golgi ([@B60]). A study has shown that downregulation of Rab1B blocked APP transport in the ER/Golgi and significantly inhibited Aβ secretion ([@B60]). Upregulation of either the early endosome protein Rab5 or the late endosome protein Rab7 increased Aβ trafficking from the cytoplasm to the lysosomes ([@B136]). Previous post mortem studies have shown that the levels of Rab7A are elevated in the brains of AD model mice. Furthermore, some recent studies have shown that Rab7A may regulate tau secretion and tangle propagation in AD ([@B192]; [@B285]). Moreover, Rab11A-positive recycling vesicles accelerated cellular Aβ accumulation (Li et al., 2012).

A large amount of literature has reported the importance of the interaction between Rab GTPases and LRRK2 in PD ([@B235]; [@B3]; [@B63]; [@B105]; [@B150]; [@B156]; [@B176]). It has been reported that autosomal dominant missense mutations within the LRRK2 gene account for 1--2% of all cases of PD ([@B171]). Similarly, variations at the LRRK2 locus also mildly increase the risk for idiopathic PD ([@B171]; [@B57]). A previous study verified that LRRK2 phosphorylates a subgroup of Rab GTPases which includes Rab7, Rab8A, and Rab10, and plays a crucial role in membrane and protein traffic ([@B81]; [@B197]; [@B235], [@B234]). Consistently with the importance of LRRK2 for PD, Rab subfamily members can be seen as regulators of membrane trafficking. Furthermore, Rab phosphorylation was found to be altered *in vivo* in all the related pathogenic processes ([@B235], [@B234]). Some reports showed that Rab35 and Rab39B may be implied in the pathogenesis of PD ([@B39]; [@B140]). There is increasing evidence that mutations in Rab29 or Rab39B are related to the impairment of membrane trafficking relevant for PD ([@B15]; [@B57]; [@B185]).

Hearing loss often results in plastic changes in the central auditory pathways, which are also related to members of the Rab family of small GTPase ([@B58]; [@B161]). Gene expression of Rab3A and Rab3GAP1 fas found to be decreased in the paraflocculus after acoustic or mechanical cochlear trauma ([@B58]; [@B161]). Moreover, early modulation of Rab GTPase gene expression in the paraflocculus may affect auditory processing by regulating the release of neurotransmitters ([@B161]).

Cone-rod dystrophy (CRD) is an inherited retinal dystrophy that belongs to the group of pigmentary retinopathies. It is characterized by primary loss of cone photoreceptors and subsequent or simultaneous loss of rod photoreceptors ([@B90]; [@B198]). A previous study has shown that mutations in Rab28 are associated with autosomal-recessive cone-rod dystrophy ([@B198]). Rab28 is located in the basal body and ciliary rootlet, where it plays a crucial role in ciliary transport. Other studies have shown that primary ciliogenesis is associated Rab3A, Rab6A, Rab8, and Rab11, which play an indirect role in rhodopsin transport from the photoreceptors' inner to the outer segments through the connecting cilium ([@B158]; [@B207]; [@B118]).

The Arf Subfamily in Non-Neoplastic Cerebral Diseases
=====================================================

Arf GTPases are a subfamily of proteins in the Ras superfamily that were identified as cargo displacement factors ([@B103]). The roles of Arf GTPases include protein trafficking, lipid metabolism and trafficking, as well as actin remodeling in eukaryotic cells via their regulated GTP cycle ([@B59]; [@B104]). According to sequence homology, there are four main classes of Arf proteins in mammals, namely Class I (Arf1--3), Class II (Arf4--5), Class III (Arf6), and unclassified members ([@B195]; [@B104]). Arf1 is the first member of this small GTPase subfamily, which is viewed as key regulators of eukaryotic cell organization ([@B110]; [@B104]). Mutations in Arf1 have been shown to be related to autosomal recessive periventricular heterotopia, a disorder that leads to severe malformation of the cerebral cortex ([@B217]).

In the last two decades, a series of cerebral diseases associated with Arf GTPases have been studied ([Table 3](#T3){ref-type="table"}). Previous studies have shown that many Arf-regulated ER--Golgi trafficking processes are defective in ALS ([@B208]; [@B267]; [@B288]; [@B11]). Moreover, a study has shown that regulation of Arf signaling reverses mutant protein toxicity in ALS by decreasing ER stress and stimulating various types of autophagy in cell lines and animal models ([@B288]). Recent studies have shown that Arl proteins which belong to Arf GTPases are associated with retinitis pigmentosa ([@B261]; [@B289]; [@B93]). In the pathogenetic process of retinitis pigmentosa, Arl2/Arl3 signaling plays important roles in photoreceptor function by regulating lipid-modified membrane-associated proteins ([@B93]). The formation of a ternary complex between Arl3, its cognate GAP RP2 and its retinal effector HRG4 is also of great importance for photoreceptor function ([@B262]). In a rodent model, regulating the activities of Arl3 GAP can reduce the severity of photoreceptor disease ([@B289]).

The Ran Subfamily and Unclassified Ras Superfamily Members in Non-Neoplastic Cerebral Diseases
==============================================================================================

Ran (Ras-related Nuclear protein) is generally encoded by a single ortholog in eukaryotes ([@B189]). The classic function of Ran is to regulate the cycle of nuclear import and export ([@B189]). There are few literature reports on the relationship between Ran and cerebral diseases ([Table 3](#T3){ref-type="table"}). A study indicated that the expression of Ran is reduced in AD, and Ran is a pivotal molecule in nucleocytoplasmic transport in AD pathophysiology ([@B152]).

Ran also plays crucial roles in frontotemporal lobe degeneration (FTLD) by regulating TDP-43 induced retinal neurodegeneration ([@B269]). FTLD comprises a group of disorders, and is clinically characterized by behavioral and personality changes, language impairment, as well as deficits in executive functioning, and is pathologically associated with degeneration of frontal and temporal lobes ([@B159]; [@B179]). The expression of Ran is found to be reduced by nuclear depletion of TDP-43 in a Grn-KO induced rodent model of retinal neuronal loss ([@B269]). Retinal neurodegeneration as a new phenotype involves the reciprocal loss of Ran in progranulin-deficient FTLD via an underlying mechanism related to nuclear TDP-43 ([@B269]). There are also some unclassified members in the Ras superfamily of small GTPases ([@B195]), and these also play vital roles in cerebral diseases. [@B78] studied synucleinopathy-induced expression changes in the mouse brain and identified 49 midbrain/brainstem-specific transcriptional dysregulations, including Rabl2A downregulation. Mitochondrial Rho GTPase 1 (MIRO1), which is encoded by the *rhoT1* gene ([@B71]; [@B243]; [@B122]), is involved in mitochondrial homeostasis and apoptosis, as well as PD and cancer ([@B4]; [@B106]; [@B212]; [@B219]; [@B259]; [@B122]). A recent study showed that MIRO1 is a potential adaptor for microtubule based peroxisome motility in mammalian cells ([@B31]). Another study has revealed that Rab20 is related to a genetic mechanism of longitudinal cognitive changes during the transition period from mild cognitive impairment to AD ([@B126]). [@B138] found that Rab20 is substantially upregulated during the acute phase of brain inflammation, and also plays crucial roles in the subsequent inflammatory responses in the brain.

Conclusion
==========

Knowledge about the roles of the Ras superfamily of small GTPases in cerebral diseases has considerably grown in the past 30 years. Currently, many research teams all over the world are also trying to identify novel small GTPases, which can be viewed as new regulators and effectors that control the crucial structure and biological functions affected by cerebral diseases. In particular, these important small GTPases have improved the development and applications of cellular and animal disease models. In this review, we mainly discussed how Ras-superfamily GTPases contribute to a range of human cerebral diseases as specific effectors in a series of complex mechanisms. Finally, a helpful summary of all described small GTPases from the Ras superfamily that play a role in cerebral diseases is shown schematically in [Tables 1](#T1){ref-type="table"}--[3](#T1){ref-type="table"}. Therefore, seeking treatment solutions for the related diseases by identifying the as-yet unknown physiological or pathological functions of more than 167 Ras superfamily members will open new research directions and fields in the following decades.
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